Physician profile
Dwayne O Williams
NPI 1689740003
$17,068.22
in general payments reported to CMS, 2019-2025
64 companies · $2,129 in 2025
The $2,129 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,321 · 2020: $2,035 · 2021: $4,078 · 2022: $2,268 · 2023: $2,258 · 2024: $1,980 · 2025: $2,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,366.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,560.90 | 2021 | |
| Novo Nordisk INC | $1,105.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $974.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $906.84 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Pfizer INC. | $838.75 | 2019-2025 | |
| Abbott Laboratories | $810.83 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $738.53 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $733.66 | 2022-2025 | |
| Glaxosmithkline, LLC. | $646.96 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $591.46 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $575.97 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $559.49 | 2019-2025 | Vraylar |
| Nestle Healthcare Nutrition INC. | $527.04 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $431.77 | 2019-2022 | |
| Redhill Biopharma INC. | $414.70 | 2020-2023 | Talicia |
Show all 63 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwayne Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.